ArticleEuropean journal of translational myology2025
Key cell cycle genes in cervical cancer and their potential role in neuromuscular complications: a bioinformatics perspective.
Article in European journal of translational myology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification of miR-21-5p and miR-21-3p regulated hub genes and drug repurposing targets in cervical cancer: an integrative computational analysis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to identify key cell cycle-related genes involved in cervical cancer progression using comprehensive bioinformatics analyses and to explore their potential implications in neuromuscular complications associated with cancer pathology or treatment. Gene expression profiles related to cervical cancer (GSE63514, GSE6791, GSE52903, and GSE9750) were retrieved from the GEO database. Differentially Expressed Genes (DEGs) distinguishing tumor tissues from normal tissues were determined through Venn diagram analysis. Functional enrichment was conducted via Gene Ontology (GO) and KEGG pathway analyses. A Protein-Protein Interaction (PPI) network was constructed using the STRING database, and core hub genes were screened through Cytoscape. Validation of selected genes was performed using GEPIA. A total of 117 DEGs were identified, with 89 upregulated and 28 downregulated genes. In this case, five hub genes-CDK1, CCNA2, CDC20, TOP2A, and EXO1-displayed significant overexpression in cervical cancer tissues with p values lower than 0.05. It is noteworthy that CCNA2 was associated with increased tumor stage and worse Disease-Free Survival (DFS), and CDK1 with worse Overall Survival (OS). These genes play crucial roles in the regulatory circuits of the cell cycle, and their altered expression may impact a range of cellular processes beyond cancer, such as the neuromuscular signalling abnormalities seen in some patients with cervical cancer. The specific genes associated with the cell cycle can act as prognostic biomarkers and may also have an influence in mediating neuromuscular complications due to their impact on mitotic control and molecular signaling pathways throughout the body. This latter aspect is helpful for the prognosis of cancer, including cervical cancer, as well as for the multidisciplinary treatment of neuromuscular symptoms that some cervical cancer patients may have.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.